Oncology Chemotherapy I
Study Course Implementer
Residency Speciality
-
About Study Course
Objective
Learning Outcomes
Knowledge
1.Knowledge of the epidemiology of tumours, primary and secondary prevention, pathogenesis, clinical manifestations, laboratory and radiological diagnostics and therapy principles.
Skills
1.To diagnose tumours according to the clinical picture, ability to select the most appropriate examination methods and interpret their data, to understand the organisation principles of the flow of haematology-oncology patients and organically integrate in it; ability to assess therapy principles of oncological diseases depending on the tumour localisation.
Competences
1.General physical examination, personal diseases and collection of family anamnesis (20); interpretation of laboratory and radiological examinations (20); participation and assistance during different surgical manipulations within the framework of the rotation cycles.
Assessment
Individual work
|
Title
|
% from total grade
|
Grade
|
|---|---|---|
|
1.
Individual work |
-
|
-
|
|
Additional literature studies and discussions with the colleagues having the right to teach, record of the performed manipulations.
|
||
Examination
|
Title
|
% from total grade
|
Grade
|
|---|---|---|
|
1.
Examination |
-
|
-
|
|
Full class attendance is mandatory. Exam consists: 50% - discussion about theoretical questions, 50% - 3 clinical cases, prepare and presentation.
|
||
Study Course Theme Plan
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
On site
|
Auditorium
|
Topics
|
Oncology. Education in the speciality. Registry of cancer pacients.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
On site
|
Auditorium
|
Topics
|
Epidemiology. Risk factors and prevention.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
Principles of team work in oncology.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
Cancerogenesis.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
Molecular biology and diagnostic options.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
Metastatic tumours of unknown localisations. Differential diagnosis. Treatment.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
Congenital tumours.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
Classification of chemotherapy drugs, mechanisms of action, doses calculation and regime. Premedication.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
Toxicity of chemotherapy drugs. Prevention and treatment.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
Nausea and vomiting treatment.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
Diagnostic and principles of treatment for myelosuppression. Febrile neutropenia.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
Bone metastases. Bisphosphonates and RANKL inhibitors.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
Target therapy, historical development, classification.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
EGFR inhibitors.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
VEGFR inbibitors. Indication and toxicity.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
HER-2 receptors, indication for treatment with anti HER-2 inhibitors. Cardiotoxicity. Prevention.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
Small molecule TKI. Indication and toxicity.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
Monoclonal antibodies. Incication and toxicity.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
Immunotherapy in oncology. Historical development, classification.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
PD-L1 and PD-1 inhibitors, indication and toxicity.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
CTLA-4 inhibitors, indication and toxicity.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
Evaluation of the effectiveness of immunotherapy. Pseudoprogression.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
Autoimmune toxicity of immunotherapy.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
Immune system stimulators in oncology. Interferon. Indication and toxicity,.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
Clinical research. Good clinical practice.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
Clinical research process, documentation.
|
Bibliography
Required Reading
DeVita, Hellman, and Rosenberg's. Cancer: Principles & Practice of Oncology, 11th edition, 2018
Adami H.O., Hunter D., Trichopoulos D. Textbook of Cancer Epidemiology. 2nd edition, Oxford University Press, 2007.
Schmoll H.J., Van’t Veer L., Vermorken J., Schrijvers D. Handbook of cancer diagnosis and treatment evaluation. Informa Heathcare USA, Inc., 2009.
Schrijvers D., Senn H.J., Mellstedt H., Zakotnik B. Handbook of cancer prevention. Informa UK Ltd., 2008.
Mellstedt H., Schrijvers D., Bafaloukos D., Greil R. Handbook of principles of translational research. Informa UK Ltd., 2007.
Catane R., Cherny N.I., Kloke M., Tanneberger S., Schrijvers D. Handbook of advanced cancer care. Taylor&Francis, 2006.